A novel synthetic analog of 5, 8-disubstituted quinazolines blocks mitosis and induces apoptosis of tumor cells by inhibiting microtubule polymerization

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Tian, Wei ^b   Qin, Lili ^b   Song, Qiaoling ^a   He, Li ^a   Ai, Midan ^a   Jin, Yi ^a   Zhou, Zuyu ^a   You, Song ^b   Long, Yaqiu ^a   Yu, Qiang ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

5,8 QUINAZOLINE DERIVATIVE; COLCHICINE; NOCODAZOLE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE PHASE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MICROTUBULE ASSEMBLY; MITOSIS INHIBITION; POLYMERIZATION; PROTEIN PHOSPHORYLATION; TUMOR CELL;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COLCHICINE; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; G2 PHASE; HUMANS; MICROTUBULES; MITOSIS; MITOTIC SPINDLE APPARATUS; PHOSPHORYLATION; PHOSPHOTYROSINE; QUINAZOLINES; TUBULIN;

EID: 77956418972     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010499     Document Type: Article

References (38)

1. Margolis RL, Wilson L (1998) Microtubule treadmilling: what goes around comes around. Bioessays 20: 830-836.
2. Kovacs P, Csaba G (2006) Effect of drugs affecting microtubular assembly on microtubules, phospholipid synthesis and physiological indices (signalling, growth, motility and phagocytosis) in Tetrahymena pyriformis. Cell Biochem Funct 24: 419-429.
3. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, et al. (2004) Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule-targeted drugs in killing human cancer cells. Mol Cancer Ther 3: 661-669.
4. Masuda A, Maeno K, Nakagawa T, Saito H, Takahashi T (2003) Association between mitotic spindle checkpoint impairment and susceptibility to the induction of apoptosis by anti-microtubule agents in human lung cancers. Am J Pathol 163: 1109-1116.
5. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, et al. (2002) The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Ther 1: 1201-1209.
6. Wilson L, Panda D, Jordan MA (1999) Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct Funct 24: 329-335.
7. Mani S, Macapinlac M, Jr., Goel S, Verdier-Pinard D, Fojo T, et al. (2004) The clinical development of new mitotic inhibitors that stabilize the microtubule. Anticancer Drugs 15: 553-558.
8. Jordan MA, Wilson L (2004) Microtubule as a target for anticancer drugs. Nat Rev Cancer 4: 253-265.
9. Hong FD, Chen J, Donovan S, Schneider N, Nisen PD (1999) Taxol, vincristine or nocodazole induces lethality in G1-checkpoint-defective human astrocytoma U373MG cells by triggering hyperploid progression. Carcinogenesis 20: 1161-1168.
10. Karbowski M, Spodnik JH, Teranishi M, Wozniak M, Nishizawa Y, et al. (2001) Opposite effects of microtubule-stabilizing and microtubule-destabilizing drugs on biogenesis of mitochondria in mammalian cells. J Cell Sci 114: 281-291.
11. Jordan MA, Wilson L (1998) Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10: 123-130.
12. Kelling J, Sullivan K, Wilson L, Jordan MA (2003) Suppression of centromere dynamics by taxol in living osteosarcoma cells. Cancer Res 63: 2794-2801.
13. Okouneva T, Hill BT, Wilson L, Jordan MA (2003) The effects of vinflurine, vincrelbine, and vinblastine on centromere dynamics. Mol Cancer Ther 2: 427-436.
14. Wall ME, Wani MC (1996) Camptothecin and taxol: from discovery to clinic. J Ethnopharmacol 51: 239-253; discussion 253-254.
15. Dumontet C, Sikic BI (1999) Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol 17: 1061-1070.
16. Gottesman MM (2002) Mechanisms of cancer drug resistance. Annu Rev Med 53: 615-627.
17. Rowinsky EK, Tolcher AW (2001) Antimicrotubule agents. In: Devita VT, Jr., Hellman S, Rosenberg SA, eds. Cancer Principles and practice, Ed. 6. Philadelphia: Lippincott Williams and Willkins. pp 431-452.
18. Shin DY, Choi TS (2004) Oocyte-based screening system for anti-microtubule agents. J Reprod Dev 50: 647-52.
19. Jin Y, Li H-Y, Lin L-P, Tan J, Ding J, et al. (2005) Synthesis and Antitumor Evaluation of Novel 5-Substituted 4-Hydroxy-8-nitroquinazolines as EGFR signaling-targeted Inhibitors. Bioorg Med Chem 13: 5613-5622.
20. Jin Y, Zhou Z-Y, Tian W, Yu Q, Long YQ (2006) 49-Alkoxyl substitution enhancing the anti-mitotic effect of 5-(39,49,59-substituted)anilino-4-hydroxy -8- nitroquinazolines as a novel class of anti-microtubule agents. Bioorg Med Chem Lett 16: 5864-5869.
21. Yoshida D, Hoshino S, Shimura T, Takahashi H, Teramoto A (2000) Druginduced apoptosis by anti-microtubule agent, estramustine phosphate on human malignant glioma cell line, U87MG; in vitro study. J Neurooncol 47: 133-140.
22. Leoni LM, Hamel E, Genini D, Shih H, Carrera CJ, et al. (2000) Indanocine, a Microtubule-Binding Indanone and a Selective Inducer of Apoptosis in Multidrug- Resistant Cancer Cells. J Natl Cancer Inst 92: 217-224.
23. Chen JG, Horwitz SB (2002) Differential mitotic responses to microtubulestabilizing and-destabilizing drugs. Cancer Res 62: 1935-1938.
24. Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH (2002) G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest 110: 91-99.
25. Jordan MA, Thrower D, Wilson L (1992) Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. J Cell Sci 102: 401-416.
26. Gupta S, Bhattacharyya B (2003) Antimicrotubular drugs binding to vinca domain of tubulin. Mol Cell Biochem 253: 41-47.
27. Zanelli GD, Quaia M, Robieux I, Bujor L, Santarosa M, et al. (1997) Paclitaxel as a radiosensitiser: a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer 33: 486-492.
28. Jordan MA, Toso RJ, Thrower D, Wilson L (1993) Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proc Natl Acad Sci USA 90: 9552-9556.
29. Mollinedo F, Gajate C (2003) Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 8: 413-450.
30. Taylor SS, Scott MI, Holland AJ (2004) The spindle checkpoint: a quality control mechanism which ensures accurate chromosome segregation. Chromosome Res 12: 599-616.
31. Tahir SK, Han EK, Credo B, Jae HS, Pietenpol JA, et al. (2001) A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Cancer Res 61: 5480-5485.
32. Martello LA, McDaid HM, Regl DL, Yang CP, Meng D, et al. (2000) Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 6: 1978-1987.
33. Panda D, Miller HP, Islam K, Wilson L (1997) Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci U S A 94: 10560-10564.
34. Photiou A, Shah P, Leong LK, Moss J, Retsas S (1997) In vitro synergy of paclitaxel (taxol) and vinorelbine (navelbine) against human melanoma cell lines. Eur J Cancer 33: 463-70.
35. Saxena NK, Titus MA, Ding X, Floyd J, Srinivasan S, et al. (2004) Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J 18: 1612-1614.
36. Weiderhold KN, Randall-Hlubek DA, Polin LA, Hamel E, Mooberry SL (2006) CB694, a novel antimitotic with antitumor activities. Int J Cancer 118: 1032-1040.
37. Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, et al. (2004) BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo. Cancer research 64: 4621-4628.
38. Martin JH, Symonds A (2002) Synergistic antitumor effect of a combination of toremifene and interferon-alpha on ZR-75-1 human breast cancer cells: dependence on interferon-alpha subtype. Oncol Rep 9: 379-382.